Les inhibiteurs du cotransporteur du sodium-glucose de type 2 pour l'insuffisance cardiaque avec fraction d'éjection réduite

Clinical question: What is the role of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with chronic heart failure with reduced ejection fraction?Bottom line: An SGLT2i reduces mortality, heart failure hospitalizations, and improves quality of life when added to other medications for heart failure with reduced ejection fraction—with or without diabetes. Compared with placebo, for every 100 patients treated with SGLT2i for about 1.5 years, about 2 fewer will die, roughly 4 fewer will be hospitalized for heart failure, and roughly 7 more will have improved quality of life.